Home » FDA Fast Tracks Remedy Pharmaceuticals’ CIRARA
FDA Fast Tracks Remedy Pharmaceuticals’ CIRARA
Remedy Pharmaceuticals has snagged FDA fast track designation for Cirara for the treatment of large hemispheric infarctions.
Cirara inhibits Sur1-Trpm4 channels, which can lead to edema, midline shift, increased intracranial pressure and brain herniation.
The company plans to initiate a Phase 3 study evaluating the candidate by the end of the year.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May